MHRA opened an investigation into clinics promoting unregulated peptides
The MHRA began investigating UK clinics making therapeutic claims about unregulated peptide products. BPC-157 was reported as the first compound named. The regulator's stated position is that the products are unlicensed and the marketing has run ahead of the evidence.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.